Also known as: Vertex, Vertex Pharmaceuticals
Vertex Pharmaceuticals is an American biopharmaceutical company focused on developing and commercializing medicines for serious diseases. It is best known for its cystic fibrosis franchise and has expanded into cell and genetic therapy programs.
Vertex's Phase 3 RAINIER trial of povetacicept in IgA nephropathy met its primary endpoint with a 52% UPCR reduction. The FDA granted rolling review, and Vertex plans full BLA submission by end of March. Shares rose on the news and analyst upgrades.
CRISPR Therapeutics said CASGEVY launch momentum is building and multiple pipeline assets could generate data in the next 12 to 18 months. The company also highlighted zugo-cel progress in oncology and autoimmune disease.
Vertex secured a Germany reimbursement agreement for CASGEVY and signed a WuXi Biologics pact for a preclinical autoimmune T-cell engager. The moves add to efforts to build revenue beyond cystic fibrosis.
Vertex completed the rolling BLA submission for povetacicept in IgA nephropathy after positive Phase 3 RAINIER interim data. The company plans to use a Priority Review Voucher to accelerate FDA review.
Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.
CRISPR Therapeutics reported a $581.6 million net loss in 2025 with revenue of just $3.5 million, while continuing to advance its gene-editing pipeline including the approved CASGEVY therapy and next-generation CAR T cell programs. The company maintains strategic partnerships and expects current funds to support operations for at least 24 months.
CRISPR Therapeutics reported a Q4 2025 loss of $1.37 per share, missing estimates, with revenues of $0.9 million falling short of expectations. The company's partner Vertex recorded $54 million in Casgevy sales for the quarter, with regulatory submissions for pediatric label expansion planned for early 2026.
The cell therapy manufacturing market is projected to reach $14.01 billion by 2035, with CAR-T therapies dominating at 65% market share. Recent FDA approvals for new CAR-T indications and Japanese regulatory acceleration highlight growing clinical adoption, while research advances include new anti-aging protein platforms and CRISPR-based treatments.
The global orphan drugs market is projected to grow from $223.76 billion in 2023 to $486.51 billion by 2032, with North America leading at 38% market share. Over 500 orphan drugs are approved with more than 800 candidates in clinical trials, driven by regulatory incentives and major pharmaceutical company investments in rare disease therapies.
Global orphan drug sales are forecast to reach $409 billion by 2032, representing one-fifth of prescription drug sales, with Johnson & Johnson and Argenx leading the market amid regulatory uncertainty.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07584434 |
A Phase 1, First-in-human Study of VX-433 |
NOT_YET_RECRUITING | PHASE1 |
| NCT07570069 |
Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants |
NOT_YET_RECRUITING | PHASE1 |
| NCT07538570 |
Evaluation of Pain Treatment After Total Knee Arthroplasty |
RECRUITING | PHASE4 |
| NCT07501702 |
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis |
RECRUITING | PHASE2 |
| NCT07463430 |
Suzetrigine for Non-Mastectomy Breast Surgery |
ENROLLING_BY_INVITATION | PHASE4 |
| NCT07437105 |
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants |
RECRUITING | PHASE1 |
| NCT07378865 |
Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants |
RECRUITING | PHASE1 |
| NCT07349394 |
Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants |
COMPLETED | PHASE1 |
| NCT07283770 |
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants |
RECRUITING | PHASE1 |
| NCT07231419 |
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy |
RECRUITING | PHASE3 |
